Literature DB >> 16914566

Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma.

Sonja Hahtola1, Soile Tuomela, Laura Elo, Tiina Häkkinen, Leena Karenko, Boguslaw Nedoszytko, Hannele Heikkilä, Ulpu Saarialho-Kere, Jadwiga Roszkiewicz, Tero Aittokallio, Riitta Lahesmaa, Annamari Ranki.   

Abstract

PURPOSE: Increased production of Th2 cytokines characterizes Sezary syndrome, the leukemic form of cutaneous T-cell lymphomas (CTCL). To identify the molecular background and to study whether shared by the most common CTCL subtype, mycosis fungoides, we analyzed the gene expression profiles in both subtypes. EXPERIMENTAL
DESIGN: Freshly isolated cells from 30 samples, representing skin, blood, and enriched CD4(+) cell populations of mycosis fungoides and Sezary syndrome, were analyzed with Affymetrix (Santa Clara, CA) oligonucleotide microarrays, quantitative PCR, or immunohistochemistry. The gene expression profiles were combined with findings of comparative genomic hybridization of the same samples to identify chromosomal changes affecting the aberrant gene expression.
RESULTS: We identified a set of Th1-specific genes [e.g., TBX21 (T-bet), NKG7, and SCYA5 (RANTES)] to be down-regulated in Sezary syndrome as well as in a proportion of mycosis fungoides samples. In both Sezary syndrome and mycosis fungoides blood samples, the S100P and LIR9 gene expression was up-regulated. In lesional skin, IL7R and CD52 were up-regulated. Integration of comparative genomic hybridization and transcriptomic data identified chromosome arms 1q, 3p, 3q, 4q, 12q, 16p, and 16q as likely targets for new CTCL-associated gene aberrations.
CONCLUSIONS: Our findings revealed several new genes involved in CTCL pathogenesis and potential therapeutic targets. Down-regulation of a set of genes involved in Th1 polarization, including the major Th1-polarizing factor, TBX21, was for the first time associated with CTCL. In addition, a plausible explanation for the proliferative response of CTCL cells to locally produced interleukin-7 was revealed.

Entities:  

Mesh:

Year:  2006        PMID: 16914566     DOI: 10.1158/1078-0432.CCR-06-0532

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Authors:  Thorbjørn Krejsgaard; Andreas Willerslev-Olsen; Lise M Lindahl; Charlotte M Bonefeld; Sergei B Koralov; Carsten Geisler; Mariusz A Wasik; Robert Gniadecki; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

Review 2.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

3.  Single-cell heterogeneity in Sézary syndrome.

Authors:  Terkild Brink Buus; Andreas Willerslev-Olsen; Simon Fredholm; Edda Blümel; Claudia Nastasi; Maria Gluud; Tengpeng Hu; Lise M Lindahl; Lars Iversen; Hanne Fogh; Robert Gniadecki; Ivan V Litvinov; Jenny L Persson; Charlotte Menné Bonefeld; Carsten Geisler; Jan Pravsgaard Christensen; Thorbjørn Krejsgaard; Thomas Litman; Anders Woetmann; Niels Ødum
Journal:  Blood Adv       Date:  2018-08-28

4.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Authors:  Michael K Kiessling; Patrick A Oberholzer; Chandrani Mondal; Maria B Karpova; Marie C Zipser; William M Lin; Michael Girardi; Laura E Macconaill; Sarah M Kehoe; Charlie Hatton; Lars E French; Levi A Garraway; Gernot Polier; Dorothee Süss; Claus-Detlev Klemke; Peter H Krammer; Karsten Gülow; Reinhard Dummer
Journal:  Blood       Date:  2011-01-05       Impact factor: 22.113

5.  Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.

Authors:  Anita Kumar; Santosha Vardhana; Alison J Moskowitz; Pierluigi Porcu; Ahmet Dogan; Jason A Dubovsky; Matthew J Matasar; Zhigang Zhang; Anas Younes; Steven M Horwitz
Journal:  Blood Adv       Date:  2018-04-24

6.  Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage.

Authors:  Anna Vasku; Julie Bienertova Vasku; Miroslav Necas; Vladimir Vasku
Journal:  J Biomed Biotechnol       Date:  2010-06-29

Review 7.  T-cell receptor signaling in peripheral T-cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway.

Authors:  Kathrin Warner; Nicole Weit; Giuliano Crispatzu; Joan Admirand; Dan Jones; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

Review 8.  Lessons learned from gene expression profiling of cutaneous T-cell lymphoma.

Authors:  B O Dulmage; L J Geskin
Journal:  Br J Dermatol       Date:  2013-12       Impact factor: 9.302

9.  Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides.

Authors:  Benjamin F Chong; Adam J Wilson; Heather M Gibson; Mikehl S Hafner; Yu Luo; Carrie J Hedgcock; Henry K Wong
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

10.  Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome.

Authors:  Heather M Gibson; Anjali Mishra; Derek V Chan; Timothy S Hake; Pierluigi Porcu; Henry K Wong
Journal:  J Invest Dermatol       Date:  2012-09-06       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.